Treatment of Retinoblastoma with Family History or Confirmed Germline RB1 Mutation
This first-line protocol applies to patients with bilateral retinoblastoma, a confirmed germline RB1 mutation, or a family history of retinoblastoma, who present without high-risk pathological features — specifically no extraocular extension, choroidal invasion, or optic nerve invasion.
Clinical Scenario
A family history of retinoblastoma, a confirmed germline RB1 mutation, or bilateral disease each independently qualify a patient for this structured approach. The absence of high-risk features — no extraocular extension, no choroidal or optic nerve invasion — defines the therapeutic boundary for this protocol. Family history of retinoblastoma is a recognised indication for intravenous chemotherapy-based management even when other risk factors are not present.
Treatment Approach (Partial Overview)
The backbone of this protocol is systemic intravenous chemotherapy administered in regular cycles, often combined with focal consolidation techniques. The complete regimen — including drug selection, cycle count, sequencing, and the combination strategy — is available in the full structured protocol.
Treatment Goal
Complete regression of the tumor, with flat scars and fully regressed lesions.
References
DOI: 10.4103/ijo.IJO_721_20
- Current indications for IVC include patients with bilateral disease, confirmed germline mutation, family history of retinoblastoma, or cases with suspected optic nerve or choroidal invasion.
- IVC usually consists of 2, 3 or 4 chemotherapeutic agents administered monthly through a central or peripheral catheter for a total of 6‑9 consecutive cycles.
- Focal therapies are often used for tumor consolidation in conjunction with IVC or IAC.
View source ↗